BioCentury
ARTICLE | Company News

Galapagos, Roche end fibrosis, COPD deal

March 9, 2013 1:54 AM UTC

Galapagos N.V. (Euronext:GLPG; Pink:GLPYY) said Roche (SIX:ROG; OTCQX:RHHBY) terminated an amended 2009 deal to discover and develop treatments for chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis. Galapagos regains worldwide rights to all assets that were discovered under the deal, including fibrosis assays and targets. The biotech also will receive a EUR 5.8 million ($7.5 million) payment from Roche for work completed under the deal in 2012. According to Galapagos, Roche ended the deal as a result of "strategy changes in therapy area" at the pharma. Roche could not be reached for comment. Galapagos, which said it plans to find another partner, was down EUR 1.15 to EUR 19.25 on Friday. ...